Results 191 to 200 of about 39,275 (210)

Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes

Expert Review of Clinical Pharmacology, 2017
Thomas Fremming Dejgaard, Sten Madsbad
exaly  

GLP-1 receptor agonists and obesity care

BMJ
Juan V A, Franco, Jen, Manne-Goehler
openaire   +2 more sources

Side effects of GLP-1 receptor agonists

BMJ
Jennifer, Manne-Goehler, Juan, Franco
openaire   +2 more sources

Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists

New England Journal of Medicine
Govind, Persad, Johan L, Dellgren, Ezekiel J, Emanuel   +2 more
openaire   +6 more sources

Treatment with GLP-1 Receptor Agonists

2018
Madsbad, Sten, Holst, Jens J.
openaire   +2 more sources

GLP-1 receptor agonists for type 2 diabetes

The Lancet, 2009
de Block, Christophe, Van Gaal, Luc
openaire   +3 more sources

Robust anti‐obesity and metabolic effects of a dual GLP ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Diabetes, Obesity and Metabolism, 2016
James L Trevaskis, Alessandra Rossi
exaly  

GLP-1 receptor agonists in clinical practice

Medicina Clínica (English Edition)
openaire   +2 more sources

The promise and hope of GLP-1 receptor agonists

The Lancet Diabetes & Endocrinology
Priya, Sumithran, Jamy, Ard
openaire   +2 more sources

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Lancet, The
Ania M Jastreboff
exaly